TargetMol

Teglarinad chloride

Product Code:
 
TAR-T26254
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T26254-25mg25mg£962.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26254-50mg50mg£1,532.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26254-100mg100mg£2,336.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Teglarinad chloride (GMX-1777 and EB1627) is an effective NAMPT inhibitor. GMX1777 has potential antineoplastic activity. In vivo, GMX1777 is rapidly converted into GMX1778 through hydrolytic cleavage of a carbonate ester bond. GMX1778 appears to antagonize NF-kB transcription, resulting in the induction of tumor cell apoptosis.
CAS:
432037-57-5
Formula:
C30H43Cl2N5O8
Molecular Weight:
672.6
Purity:
0.98
SMILES:
[Cl-].COCCOCCOCCOCCOC(=O)OC[n+]1ccc(NC(NC#N)=N/CCCCCCOc2ccc(Cl)cc2)cc1

References

1. Preyat N, Leo O. Complex role of nicotinamide adenine dinucleotide in the regulation of programmed cell death pathways. Biochem Pharmacol. 2016 Feb 1;101:13-26. doi: 10.1016/j.bcp.2015.08.110. Epub 2015 Sep 3. PubMed PMID: 26343585. 2. Chan M, Gravel M, Bramoull? A, Bridon G, Avizonis D, Shore GC, Roulston A. Synergy between the NAMPT inhibitor GMX1777(8) and pemetrexed in non-small cell lung cancer cells is mediated by PARP activation and enhanced NAD consumption. Cancer Res. 2014 Nov 1;74(21):5948-54. doi: 10.1158/0008-5472.CAN-14-0809. Epub 2014 Aug 21. PubMed PMID: 25145669. 3. Olesen UH, Petersen JG, Garten A, Kiess W, Yoshino J, Imai S, Christensen MK, Fristrup P, Thougaard AV, Bj?rkling F, Jensen PB, Nielsen SJ, Sehested M. Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase. BMC Cancer. 2010 Dec 12;10:677. doi: 10.1186/1471-2407-10-677. PubMed PMID: 21144000; PubMed Central PMCID: PMC3019212. 4. Bi TQ, Che XM. Nampt/PBEF/visfatin and cancer. Cancer Biol Ther. 2010 Jul 15;10(2):119-25. doi: 10.4161/cbt.10.2.12581. Epub 2010 Jul 3. Review. PubMed PMID: 20647743.